Oligodendrocytes In Multiple System Atrophy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. A defining pathological feature is the presence of glial cytoplasmic inclusions (GCIs) in oligodendrocytes, making it a primary oligodendrogliopathy.
¶ Structure and Composition
- Main component: Alpha-synuclein (α-syn)
- Filamentous nature: Made of 10-12nm filaments
- Distribution: Throughout white matter
- α-Synuclein misfolding: From neuronal to glial transmission
- Oligodendroglial vulnerability: Low proteasomal activity
- Myelin stress: Metabolic vulnerability
- Primary degeneration: Loss of myelin-producing cells
- Secondary demyelination: Due to oligodendrocyte death
- White matter lesions: On MRI
| Feature |
Description |
| GCI burden |
Correlates with disease severity |
| Neuronal loss |
Associated with GCI density |
| Axonal degeneration |
Secondary to demyelination |
- Putamen: Severe neuronal loss
- Globus pallidus: Iron deposition
- Substantia nigra: Dopaminergic neuron loss
- Inferior olivary nucleus: Neuronal loss
- Pontine nuclei: Demyelination
- Cerebellar white matter: GCI accumulation
- Phosphorylation: Ser129 phosphorylation in GCIs
- Aggregation: Toxic oligomer formation
- Transmission: Neuron-to-glia and glia-to-neuron
- ER stress: CHOP activation
- Mitochondrial dysfunction: Complex I deficiency
- Inflammation: Microglial activation
- No disease-modifying therapy: Limited treatment options
- Rapid progression: Median survival 6-9 years
- α-Synuclein targeting: Immunotherapies
- Neuroprotective agents: CoQ10, mesenchymal stem cells
- Myelin repair: Oligodendrocyte precursor activation
The study of Oligodendrocytes In Multiple System Atrophy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Jellinger KA, et al. Neuropathology of MSA. Acta Neuropathol. 2020;139(3):363-386.
- Wenning GK, et al. Multiple system atrophy. Nat Rev Dis Primers. 2022;8(1):41.
- Koga S, et al. Glial cytoplasmic inclusions in MSA. Brain. 2021;144(1):23-40.